$OPTH News

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

Optimi Health Completes Latest Production Batch Of Its MDMA Finished Drug Product; Proposed Phase 3 Trial Expected To Begin In 2027

Optimi Health to Present at the ThinkEquity Conference

Optimi Health Appoints Melanie Pump to Board of Directors

Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

Optimi Health Plans To Initiate A Phase 3 Clinical Trial Evaluating MDMA-Assisted Therapy For PTSD Authorized By Health Canada; Trial Is Expected To Begin In 2027

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Optimi Health Plans To Initiate Multisite Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy For Individuals With Major Depressive Disorder In H1 2027, With Dosing Expected To Be Complete By 2027 End

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances

Optimi Health Establishes Discretionary Equity Facility

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression